EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deviations from recommended use of liposomal bupivacaine: a real-world pharmacovigilance study using the FAERS database

Wei Ma, Jing Lu, Cheng Shen, Haoshi Gao, Wei Gao

Frontiers in Medicine · 29.05.2026 · 13

DOI: 10.3389/fmed.2026.1851787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 29.05.2026. Verfasst von Wei Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Guangzhou Xinhua University, Guangzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Liposomal bupivacaine (L-BUP) is a widely used long-acting local anesthetic, but real-world data on its post-marketing off-label use and medication error risks remain limited. This study aimed to characterize these risks to inform rational clinical use and post-marketing risk management of improved new drug formulations.

Methods

L-BUP-related safety reports were extracted from the FAERS database (Q1 2004–Q2 2025). Four disproportionality analysis methods (ROR, PRR, BCPNN, and MGPS) were applied, with a positive signal defined as simultaneously meeting all four predefined criteria. Risk signals were mapped via Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms (PTs) and Standardized MedDRA Queries (SMQs). Conventional bupivacaine (C-BUP) was used as a comparator in the sensitivity analysis to verify the specificity of risk signals.

Results

Among 19,252,329 included FAERS reports, 4,151 listed L-BUP as the primary suspect drug. Of the top 20 L-BUP positive signals, 35% were associated with deviations from recommended use. Notably, “Labeled drug–drug interaction medication error” exhibited the strongest signal (ROR = 332.7), while “Off-label use” had the highest reporting frequency, with 238 cases. At the SMQ level, medication errors yielded a positive safety signal (ROR = 4.17). Sensitivity analysis confirmed that C-BUP presented a negative signal for medication errors (ROR = 0.88) under identical analytical conditions. The number of concomitant medications was positively correlated with the incidence of serious adverse events, whereas the overall serious adverse event rate was higher for C-BUP than for L-BUP.

Conclusion

L-BUP carries significant off-label use and formulation-specific medication error risks, with a positive correlation between concomitant medication use and serious adverse events. Many of these risks are preventable. These findings support targeted clinical and regulatory risk mitigation strategies for L-BUP, and provide evidence for improved post-marketing surveillance of complex modified-release formulations.

Schlagwörter

Stichwörter der Autor:innen

FAERS databasedisproportionality analysisliposomal bupivacainemedication erroroff-label usepharmacovigilance

Autor:innen und Institutionen

  • School of Pharmacy, Guangzhou Xinhua University, Guangzhou, China.
  • Pharmacy Department, Liwan Central Hospital of Guangzhou, Guangzhou, China.
  • Department of Pharmacy, The Affiliated Children's Hospital of Xiangya School of Medicine, Central South University (Hunan Children's Hospital), Changsha, China.
  • School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
  • Department of Urology, Liwan Central Hospital of Guangzhou, Guangzhou, China.

Zitieren

APA

Ma, W., Lu, J., Shen, C., Gao, H., & Gao, W. (2026). Deviations from recommended use of liposomal bupivacaine: a real-world pharmacovigilance study using the FAERS database. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1851787

Vancouver

Ma W, Lu J, Shen C, Gao H, Gao W. Deviations from recommended use of liposomal bupivacaine: a real-world pharmacovigilance study using the FAERS database. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1851787

BibTeX
@article{Ma2026,
  author = {Ma, Wei and Lu, Jing and Shen, Cheng and Gao, Haoshi and Gao, Wei},
  title = {Deviations from recommended use of liposomal bupivacaine: a real-world pharmacovigilance study using the FAERS database},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1851787}
}
Kostenlos starten →